Top news of the week: 29.04.2022.
Career And Jobs
DNA and vaccines
For this year’s DNA Day, we reflect on the power of vaccines — and what they do and don’t have to do with DNA.
Bear market mauls another small biotech as CEO, board members exit and execs bring out the axe, hunt deals
The bear market is continuing to maul the biotech world as a small Danish biotech company specializing in rare CNS diseases is bringing out the budget axe, chopping its workforce in the US ...
Irv Weissman's lab spins out another biotech, with help of Forty Seven co-founders, to target new 'don't eat me' signal
At age 24, while in Irv Weissman's lab, Amira Barkal realized the CD24 protein was another “don’t eat me” signal for cancers. Weissman, the Stanford stem cell pioneer, had already spawned ...
Arie and Dan Belldegrun are building biotech campuses around the globe — with a newly raised $3B fund to keep the dirt flying
The biotech sector on Nasdaq may have been blighted by imploding stock prices, the generalists long gone in search of greener fields as the bears rule the once booming industry. But while ...
In a surprise move, Novartis CEO Vas Narasimhan recruits top analyst Ronny Gal as new strategy, BD chief
After a long run observing Novartis and the rest of the Big Pharma world as a top analyst, Bernstein’s Ronny Gal will now move into the upper echelon of the Swiss giant’s executive crew to ...
Can this tick biologist and her team of ‘weirdo science’ enthusiasts change the future of scientific research?
It’s rare, though far from unheard of, for scientists to leave prestigious academic appointments. But Seemay Chou’s departure made a larger splash than most. One cool, cloudy San Francisco ...
Aviv Regev recruits a ‘purple unicorn’ for the top post in the computational pillar she’s building at Genentech
Two years after Aviv Regev left her scientific abode at the Broad and journeyed west to take over as the new head of research and early development at Genentech, she’s taking another big ...
Scoop: After failing to secure more funds, a private gene therapy developer lays off staff
Last Friday, SwanBio Therapeutics laid off about one-quarter of its 60-person workforce, a person with knowledge of the matter told Endpoints News. The gene therapy biotech was unable to ...